[HTML][HTML] A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
AC Huang, R Zappasodi - Nature immunology, 2022 - nature.com
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
Mechanisms of immune activation and regulation: lessons from melanoma
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …
particularly in terms of the immune response to tumours, and has been used as a model for …
Tumour-intrinsic resistance to immune checkpoint blockade
Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …
[HTML][HTML] The clinical role of the TME in solid cancer
The highly complex and heterogenous ecosystem of a tumour not only contains malignant
cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts …
cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts …
[HTML][HTML] Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress
Malignant transformation can result in melanoma cells that resemble different stages of their
embryonic development. Our gene expression analysis of human melanoma cell lines and …
embryonic development. Our gene expression analysis of human melanoma cell lines and …
Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer
K Kulangara, N Zhang, E Corigliano… - … of pathology & …, 2019 - meridian.allenpress.com
Context.—Regulatory approval of pembrolizumab for treatment of gastric and
gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring …
gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring …
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
GT Gibney, LM Weiner, MB Atkins - The Lancet Oncology, 2016 - thelancet.com
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …
exciting era of anticancer therapy. Durable responses can be seen in patients with …
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno …
S Hendry, R Salgado, T Gevaert… - Advances in anatomic …, 2017 - journals.lww.com
Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …
implications of this response are increasingly recognized, and as immunotherapies are …
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
JN Bodor, Y Boumber, H Borghaei - Cancer, 2020 - Wiley Online Library
The emergence of immunotherapy has dramatically changed how non–small cell lung
cancer is treated, and longer survival is now possible for some patients, even those with …
cancer is treated, and longer survival is now possible for some patients, even those with …